An epidermal growth factor- (EGFR-) specific third-generation CAR was developed by Zhang et al., and the specific killing ability of CAR-modified NK-92 cells (CAR-NK-92) against renal cell carcinoma cell lines has been confirmed in vitro. Here, EGFR is linked to renal cell carcinoma.